NEW YORK (360Dx) — Swedish biopharmaceutical firm BioArctic announced today that it has partnered with Brain Biomarker Solutions (BBS) to develop new biomarkers and diagnostic methods for Alzheimer's disease.

Under the terms of the deal, BioArctic will work with BBS — a spinout of the University of Gothenburg — to identify and measure new blood- and cerebrospinal fluid-based biomarkers that can be used to diagnose Alzheimer's disease and monitor the effects of investigational treatments for the condition.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oct
02

In the last few years several molecular testing methodologies — such as immunohistochemistry, PCR, and sequencing — have been approved by the US Food and Drug Administration to aid in the management of patients with lung cancer.  

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.